HighVista Strategies LLC Sells 54,058 Shares of Roivant Sciences Ltd. $ROIV

HighVista Strategies LLC decreased its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 46.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 61,268 shares of the company’s stock after selling 54,058 shares during the quarter. HighVista Strategies LLC’s holdings in Roivant Sciences were worth $690,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp raised its stake in shares of Roivant Sciences by 4.8% during the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock worth $222,847,000 after purchasing an additional 911,827 shares in the last quarter. Two Seas Capital LP raised its stake in Roivant Sciences by 4.6% in the second quarter. Two Seas Capital LP now owns 10,598,040 shares of the company’s stock valued at $119,440,000 after buying an additional 461,733 shares during the period. Invesco Ltd. lifted its position in shares of Roivant Sciences by 3.8% in the first quarter. Invesco Ltd. now owns 9,880,526 shares of the company’s stock valued at $99,695,000 after buying an additional 365,468 shares during the last quarter. BlackBarn Capital Partners LP boosted its stake in shares of Roivant Sciences by 15.2% during the 1st quarter. BlackBarn Capital Partners LP now owns 4,750,000 shares of the company’s stock worth $47,928,000 after acquiring an additional 625,000 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in shares of Roivant Sciences by 12.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,506,400 shares of the company’s stock worth $50,787,000 after acquiring an additional 506,219 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ROIV has been the topic of several research reports. Leerink Partners reiterated an “outperform” rating and issued a $29.00 price objective on shares of Roivant Sciences in a report on Tuesday, November 11th. Weiss Ratings raised shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Saturday, October 25th. Jefferies Financial Group raised their price objective on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. Finally, HC Wainwright upped their price objective on Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $22.56.

Roivant Sciences Stock Down 0.9%

Shares of Roivant Sciences stock opened at $20.24 on Thursday. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $21.48. The company has a market capitalization of $14.08 billion, a price-to-earnings ratio of -36.14 and a beta of 1.22. The firm’s 50-day moving average price is $19.15 and its two-hundred day moving average price is $14.55.

Insider Buying and Selling at Roivant Sciences

In other news, major shareholder Vivek Ramaswamy sold 1,027,670 shares of the stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $20.33, for a total value of $20,892,531.10. Following the completion of the sale, the insider owned 34,193,406 shares of the company’s stock, valued at approximately $695,151,943.98. This represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Daniel Allen Gold sold 1,300,000 shares of the business’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $20.23, for a total transaction of $26,299,000.00. Following the completion of the transaction, the director owned 18,047,727 shares in the company, valued at approximately $365,105,517.21. The trade was a 6.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 6,707,812 shares of company stock worth $121,101,540 over the last 90 days. Insiders own 10.80% of the company’s stock.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.